Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Apr 23

PMID 35454847

Authors

Annika Kasprzak

Kathrin Nachtkamp

Norbert Gattermann

Ulrich Germing

Affiliations

Soon will be listed here.

Abstract

Prognostic stratification in patients with myelodysplastic syndrome (MDS) relies on a number of key factors. Combining such patient-related and disease-related prognostic parameters into useful assessment tools remains a challenge. The most widely used scoring systems include the international prognostic scoring system (IPSS), the revised IPSS (IPSS-R), the World Health Organization (WHO) Prognostic Scoring System (WPSS), and the new molecular IPSS (IPSS-M). Similar to the IPSS-R and the IPSS-M, the chronic myelomonocytic leukemia (CMML) prognostic scoring system (CPSS) and the CPSS molecular (CPSS-mol) are powerful and reliable prognostic tools that help to assess the individual prognosis of patients with CMML. The well-established prognostic assessment of MDS and CMML may be further augmented by additional disease-related parameters, such as somatic mutations, or patient-related factors, such as comorbidities. In this article, we briefly describe useful prognostic scoring systems for myelodysplastic syndromes and identify some open questions that require further investigation.

Citing Articles

HALP score as a novel prognostic factor for patients with myelodysplastic syndromes.

Gursoy V, Sadri S, Kucukelyas H, Hunutlu F, Pinar I, Yegen Z Sci Rep. 2024; 14(1):13843.

PMID: 38879594 PMC: 11180126. DOI: 10.1038/s41598-024-64166-6.

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada.

Yun J, Ding P, Dolley A, Cheung W Curr Oncol. 2023; 30(9):8005-8018.

PMID: 37754496 PMC: 10528038. DOI: 10.3390/curroncol30090581.

The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.

Silzle T, Blum S, Kasprzak A, Nachtkamp K, Rudelius M, Hildebrandt B Cancers (Basel). 2023; 15(14).

PMID: 37509235 PMC: 10377210. DOI: 10.3390/cancers15143572.

Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment.

Nachtkamp K, Kobbe G, Gattermann N, Germing U Dtsch Arztebl Int. 2023; 120(12):203-210.

PMID: 36718105 PMC: 10264648. DOI: 10.3238/arztebl.m2023.0005.

The value of serum IL-4 to predict the survival of MDS patients.

Liu Z, Xu X, Zheng L, Ding K, Yang C, Huang J Eur J Med Res. 2023; 28(1):7.

PMID: 36600245 PMC: 9811803. DOI: 10.1186/s40001-022-00948-w.

References

Neukirchen J . Iron chelation in MDS: still a controversial issue. Leuk Res. 2013; 38(2):145-6. DOI: 10.1016/j.leukres.2013.12.004. View

Zipperer E, Tanha N, Strupp C, Kundgen A, Nachtkamp K, Neukirchen J . The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica. 2014; 99(3):e31-2. PMC: 3943327. DOI: 10.3324/haematol.2013.101055. View

Kasprzak A, Nachtkamp K, Kondakci M, Schroeder T, Kobbe G, Kundgen A . Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes. Ann Hematol. 2020; 100(2):455-463. PMC: 7817552. DOI: 10.1007/s00277-020-04325-7. View

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P . Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2019; 105(3):640-651. PMC: 7049356. DOI: 10.3324/haematol.2018.212332. View

Wimazal F, Sperr W, Kundi M, Meidlinger P, Fonatsch C, Jordan J . Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res. 2001; 25(4):287-94. DOI: 10.1016/s0145-2126(00)00140-5. View

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

Malcovati L, Germing U, Kuendgen A, Della Porta M, Pascutto C, Invernizzi R . Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23):3503-10. DOI: 10.1200/JCO.2006.08.5696. View

Sekeres M, Swern A, Giagounidis A, List A, Selleslag D, Mittelman M . The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q). Blood Cancer J. 2018; 8(10):90. PMC: 6173782. DOI: 10.1038/s41408-018-0126-z. View

Yao C, Hou H, Lin T, Lin C, Chou W, Tseng M . Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget. 2016; 7(39):63177-63188. PMC: 5325355. DOI: 10.18632/oncotarget.11050. View

10.

Sorror M, Storer B, Storb R . Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant. 2009; 15(6):757-8. PMC: 2684868. DOI: 10.1016/j.bbmt.2009.02.007. View

11.

Ogawa S . Genetics of MDS. Blood. 2019; 133(10):1049-1059. PMC: 6587668. DOI: 10.1182/blood-2018-10-844621. View

12.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellstrom-Lindberg E . Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. Blood Adv. 2018; 2(16):2079-2089. PMC: 6113605. DOI: 10.1182/bloodadvances.2018020495. View

13.

Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji R, Sekeres M . Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2020; 35(3):835-849. PMC: 7932916. DOI: 10.1038/s41375-020-0917-7. View

14.

Bernard E, Nannya Y, Hasserjian R, Devlin S, Tuechler H, Medina-Martinez J . Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020; 26(10):1549-1556. PMC: 8381722. DOI: 10.1038/s41591-020-1008-z. View

15.

Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N . The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009; 94(5):729-32. PMC: 2675687. DOI: 10.3324/haematol.2008.002063. View

16.

Rautenberg C, Germing U, Pechtel S, Lamers M, Fischermanns C, Jager P . Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS. Blood Cancer J. 2019; 9(11):86. PMC: 6851368. DOI: 10.1038/s41408-019-0248-y. View

17.

Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L . Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2007; 22(2):313-22. DOI: 10.1038/sj.leu.2405030. View

18.

Nachtkamp K, Stark R, Strupp C, Kundgen A, Giagounidis A, Aul C . Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016; 95(6):937-44. DOI: 10.1007/s00277-016-2649-3. View

19.

van de Loosdrecht A, Westers T, Westra A, Drager A, van der Velden V, Ossenkoppele G . Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2007; 111(3):1067-77. DOI: 10.1182/blood-2007-07-098764. View

20.

Platzbecker U, Germing U, Gotze K, Kiewe P, Mayer K, Chromik J . Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017; 18(10):1338-1347. DOI: 10.1016/S1470-2045(17)30615-0. View